Uterine Fibroids Clinical Trials

A listing of Uterine Fibroids medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 593 clinical trials
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)  

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

  • 0 views
  • 20 May, 2026
  • 1 location
Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease

Comparison of Angiography-derived Fractional FLow Reserve And IntraVascular Ultrasound-guided Intervention Strategy for Clinical OUtcomes in Patients with CoRonary Artery Disease

angiography
arterial disease
stenosis
heart disease
intravascular ultrasound
  • 2 views
  • 19 Feb, 2024
  • 15 locations
The PREPARE Trial: Exercise Before Surgery to Improve Recovery in Older People With Frailty

This study evaluates whether participating in a home-based exercise program leads to lower levels of complication rates and patient-reported disability after surgery. Half of the participants will be randomized into the exercise group, while the other half will be randomized into the control group.

  • 0 views
  • 19 Feb, 2024
  • 1 location
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives:

<ul>
  • Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B
  • Dose Expansion Part B: To assess …

    multiple myeloma
    measurable disease
    line of therapy
    proteasome inhibitor
    carfilzomib
    • 0 views
    • 24 Nov, 2025
    • 8 locations
    Effects of a Multimodal Exercise Program on Physical Performance and Muscle Function in Middle-aged Patients With T2DM  

    The findings are expected to support early intervention strategies for healthy aging and serve as a valuable reference for clinical practice and the development of public health policies.ul>ul>

    • 0 views
    • 02 Dec, 2025
    • 3 locations
    Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

    This research study involves the following investigational drugs:

    <ul>
  • Ipatasertib
  • Atezolizumab
  • ul>

    probe
    lymphadenectomy
    immunostimulant
    bisphosphonate
    triple negative breast neoplasms
    • 0 views
    • 19 Feb, 2024
    • 1 location
    Cisplatin+Pembrolizumab+RT in Vulvar Cancer

    This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma.

    This research study involves the following:

    <ul>
  • Cisplatin (standard of care drug)
  • Pembrolizumab (investigational drug)
  • Radiation Therapy (standard …

    liver metastasis
    ffpe
    measurable disease
    liver metastases
    metastasis
    • 0 views
    • 19 Feb, 2024
    • 1 location
    Ibrutinib + Venetoclax in Untreated WM

    The names of the study drugs involved in this study are:

    <ul>
  • Venetoclax
  • ibrutinib
  • ul>

    growth factor
    ibrutinib
    neutrophil count
    absolute neutrophil count
    bone marrow biopsy
    • 0 views
    • 19 Feb, 2024
    • 2 locations
    Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

    The names of the study interventions involved in this study are:

    <ul>
  • Sacituzumab govitecan (IMMU-132)
  • Pembrolizumab (Keytruda; MK-3475)
  • ul>

    stage iv breast cancer
    brain metastases
    progesterone
    liver metastasis
    periodic abstinence
    • 8 views
    • 19 Feb, 2024
    • 1 location
    Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

    The name of the study intervention involved in this study is:

    <ul>
  • Implantation of a MR-guided microdevice
  • ul>

    prostatectomy
    carcinoma
    neutrophil count
    • 2 views
    • 19 Feb, 2024
    • 1 location